Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech ... preclinical development and translational medicine, Merck Research Laboratories, said in the release.

Despite the Gardasil setbacks, Merck's product portfolio continues to show strength in other areas. Keytruda, the company's flagship cancer immunotherapy drug, has demonstrated continued growth ...

Under terms of the agreement, Merck ... product. 1 “Despite the remarkable progress made in cancer treatment over the past decade, more therapeutic options are needed,” said George Addona, SVP, ...

Australian steel and aluminium exports to the U.S. represent less than 0.2% of the total value of the country's annual exports and they are not in the top 10 products Australia sells to the United ...

My first blog post in Psychology Today, Has Medicine Lost Its Mind?, occurred seven years ago about this time of the year. It marked a radical new direction for me personally as well as ...

ASX pharmaceutical companies are retaining their assets longer and advancing them to commercialisation in a bid to maximise ...

BiVACOR total artificial heart inventor Daniel Timms said it was ‘extremely rewarding’ to see the device’s progress in Australia. Picture: Supplied The implant is designed to act as a bridge ...

Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.

Picture: TikTok/nectoriouspapi Aldi Australia said the grocery chain was ... explaining there was a good reason for the tweaks to the product. “This year we’ve changed the treats slightly ...

In return, Epitopea will receive an undisclosed upfront payment and is eligible for milestone payments with the potential to total up to $300 million per product. “Epitopea has been at the ...

In return, Epitopea will receive an undisclosed upfront payment and is eligible for milestone payments with the potential to total up to $300 million per product ... development and translational ...